istration to anemic adults appears to be reasonably safe (6-8, lo) , concerns have been published regarding its administration to preterm neonates (1 1, 12). One specific concern relates to the observation that, in vitro, epo down-modulates the production of neutrophils from fetal hematopoietic progenitors (12) . If epo administration to neonates results in reduced neutrophil production, the effect on antibacterial defense, already significantly impaired in neonates (13) , would require definition. Thus, our studies were performed to assess the effect of epo administration on granulocytopoiesis and neutrophilic pool sizes, using a weanling rat model.
MATERIALS AND METHODS
Animal injections. Sprague-Dawley rats with timed pregnancies (Charles River Laboratories, Stone Ridge, NY) were housed at the University of Utah vivarium, and given free access to water and rat food. After delivery, litters were culled to six to eight pups and housed with their mothers. Beginning on the 8th to 9th day of life, six pups received three consecutive daily S.C. injections of 2000 IU/kg recombinant human epo (Ultrapure Epo, >I60 000 IU/mg, Amgen, Thousand Oaks, CA). The epo was suspended in sterile PBS with 0.02% BSA (Sigma Chemical Co., St. Louis, MO). As a control, an additional six pups received the same volume of the PBS-albumin solution per injection. Animals were injected as paired sets (one epo and one control) because the neutrophil kinetic studies could be performed on a maximum of only two animals per day. All animals were killed by COz inhalation anesthesia 48 h after the 3rd injection. Blood samples were obtained by severing the external jugular vein, and the spleen and both femurs were removed.
QuantiJication of circulating, splenic, and myeloid pools of erythroid and granulocytic cells. Circulating concentrations of nucleated blood cells were determined electronically (Coulter Electronics, Hialeah, FL). Blood smears were stained with Wright's stain and subjected to 200-cell differential counts. Reticulocyte counts were performed on smears obtained from blood incubated with methylene blue, and were corrected to a hematocrit of 0.40 L/L. Hematocrits were determined by centrifugation of microcapillary tubes (Damon/IEC Division, Needham Heights, MA).
Marrow cells were obtained from the two femurs bv flushing their contents with 5 mL of sterile a-MEM (HyClone Laborat: ries, Logan, UT), as previously described (14) . Electronic cell counts and 250-500 cell differential counts were made from the resulting suspensions. Spleen cells were obtained by mincing the organ with scissors and passing the pieces through serially smaller needles ranging from 19-gauge to 23-gauge. Electronic cell counts and smears were made from the resulting cell suspensions. The NSP in the spleen was defined as the total number of segmented neutrophils, band neutrophils, and metamyelocytes in the organ. The NSP of the entire skeletal marrow was estimated, as previously described (14) , by multiplying the NSP in the combined femurs by nine, reflecting the fact that in 10-d-old rats, the combined femurs contain about i 1 % of the total skeletal marrow 584 KOENIG AND CHRISTENSEN (1 5). The NPP in the spleen was defined as the total number of myeloblasts, promyelocytes, and myelocytes in the organ. The NPP of the entire skeletal marrow was estimated in the same way as the NSP.
Hematopoietic progenitor cell culture. Marrow and spleen cells were cultured in quadruplicate 35-mm plastic tissue culture dishes in a-MEM containing 1 % (1 500 centipoise) methylcellulose (Fisher Scientific, Norcross, GA), 30% FCS (HyClone), 1 % globulin-crystallized, deionized BSA (Sigma), and 5 x M mercaptoethanol (Eastman Organic Chemicals, Rochester, NY). Cultures of CFU-E contained lo5 cells/mL and, in the initial epo dose-response studies, concentrations of epo ranging from 0.0 to 1.0 IU/mL. In subsequent studies of CFU-E, epo concentrations of 0.25 IU/mL were used. CFU-E were enumerated after 3 d in culture using an inverted microscope.
Cultures of early progenitors (CFU-MIX, CFU-GM, and BFU-E) contained 0.5 x lo5 cells/mL, and in the initial dose-response studies, contained concentrations of epo ranging from 0.0 to 4.0 IU/mL, and SCM concentrations ranging from 0 to 20%. The SCM was prepared using previously described methods (1 6, 17) . In subsequent studies of early progenitors, epo concentrations of 2.0 IU/mL and SCM concentrations of 10% were used. In studies ofthe effect of epo on CFU-GM colony formation and neutrophil generation in vitro, 10% SCM was used and the concentration of epo was varied (0.0, 0.1, 1.0, and 10.0 IU/mL). As a control for these studies, epo that had been preneutralized (18) by incubation with antiepo antiserum (Terry Fox Laboratories, Vancouver, BC) was also tested. Early progenitors were scored after 7-9 d in culture. Colonies generated from BFU-E and from CFU-GM were identified in situ as described by Kimura et al. (19) . Colonies generated by CFU-MIX were identified in situ by the presence of tightly clustered hemoglobinized cells plus loosely arranged nonhemoglobinized cells (20) .
Data analysis. Statistics were performed using t test or paired t test, as applicable.
These studies were approved by the University of Utah Institutional Animal Care and Use Committee.
RESULTS

Hematocrits and reticulocyte concentrations during 1st 4 wk of
Ilfe. These studies were performed to select an age at which to begin epo injections in the young rats. Hematocrits and reticulocyte counts were measured in groups of at least five noninjected, apparently healthy rats at various ages, including 2 d preterm (delivered by hysterotomy), the 1st d of life, and after 5, 7, 10, 13,20, and 28 d. As shown in Figure 1 , reticulocyte counts and hematocrits diminished over the first 10-15 d of life. We selected 8-to 9-d-old rats for the epo administration studies because their reticulocyte counts and hematocrits were falling, and thus any epo-induced erythropoiesis would be more evident.
Effect of epo on generation of granulocytes in vitro. These studies were performed to determine whether epo resulted in decreased CFU-GM colony formation and reduced neutrophil generation from the progenitors of normal weanling rats in vitro
(1 1, 12). Light-density (sp gr < 1.077) marrow cells, flushed from the femurs of 8-to 9-d-old rats, were cultured in various concentrations of epo, or in epo preneutralized by incubation with antiepo antiserum. As shown in Table I , increasing concentrations of epo were associated with a diminution in CFU-GM colony formation, and with diminished neutrophil generation from hematopoietic progenitors.
Effect of epo administration on circulating cells. These studies were performed to determine whether the administration of high doses of epo to 8-to 9-d-old rats had an effect on their circulating concentrations of neutrophils. Figure 2 shows the reticulocytes, normoblasts, hematocrits, and the circulating concentrations of neutrophils, monocytes, and lymphocytes in the six pairs of weanling rats. In all cases, the reticulocyte counts, the concentrations of circulating normoblasts, and the hematocrits were higher Table 2 .
Although the absolute number of normoblasts increased in spleens and marrows, no change in the number of either postmitotic or immature neutrophils was observed.
Effect of epo administration on erythroid and granulocytic progenitors. The upper panel of Figure 3 shows the effect of increasing the concentration of epo, in vitro, on generation of CFU-E colonies from the marrow of 8-to 9-d-old rats. Because epo concentrations of 0.25 IU/mL resulted in plateau CFU-E colony generation, this concentration was used in subsequent CFU-E studies. The lower panel of Figure 3 shows the effect of increasing the concentrations of SCM on generation of CFU-GM colonies from marrow of 8-to 9-d-old rats. SCM concentrations of 10% resulted in plateau CFU-GM colony formation, and this concentration was used in subsequent studies.
The absolute number of CFU-E, CFU-GM, BFU-E, and CFU-MIX colonies in the total skeletal marrow of animals injected with either epo or control are shown in Table 3 . CFU-E colonies increased by approximately 4-fold in the epo recipients, but no effect was seen on the number of CFU-GM, BFtT-E, or CFU-MIX colonies. Epo is a hormone synthesized by peritubular renal cells (21) and reticuloendothelial cells (22) in response to hypoxia. The human gene for epo has been cloned (23, 24) and sequenced (25) , and recombinant epo has been administered to humans affected with hyporegenerative anemia secondary to defective epo production (6-8, 10, 26) . Early studies cautioned that administration of epo to humans might result in neutropenia or thrombocytopenia by diversion of multipotent progenitors into erthrocytic maturation at the expense of granulocytic and megakaryocytic production (27) . The basis for this concern included the observation of Van Zant and Goldwasser (28) that, in vitro, increasing concentrations of epo resulted in a stepwise reduction in CFU-GM colony formation. In vivo observations also suggested that epo administration might reduce neutrophil production. Specifically, Bradley et al. (29) observed that the accelerated erythropoiesis in mice made anemic by repeated phlebotomy was associated with diminished CFU-GM colony formation, but that a reduction in erythropoiesis after repeated transfusions resulted in increased numbers of CFU-GM colonies. Hellman and Grate (30) observed a smaller than normal neutrophil reserve in mice with accelerated erythropoiesis, and a larger reserve in mice with diminished erythropoiesis. Despite these observations, neither neutropenia nor diminished concentrations of CFU-GM colonies in the marrow have been observed in human adults treated with recombinant epo in doses up to 500 IU/kg three times per wk (3 1).
We have recently observed that fetal progenitors in culture are considerably more sensitive to down-modulation of neutrophil production by epo than are progenitors from adult marrow (12) . The mechanism for the epo-induced diminution in fetal neutrophil production includes: I) a diversion of a group of early clones, which would have otherwise developed into CFU-GM, into normoblast-containing colonies; 2) reduced survival of some of the CFU-GM exposed to high concentrations of epo; and 3) a diminished number of neutrophils in the surviving CFU-GM exposed to high concentrations of epo.
Our studies were undertaken to evaluate the effect of epo administration on neutrophil pool sizes and production using a weanling rat model. In vitro, high concentrations of epo reduced CFU-GM colony formation, similar to that observed in studies of human fetal progenitors (1 1, 12) . Although epo caused a significant diminution in the numbers of neutrophils generated, there appeared to be little overall effect on macrophage generation. In vivo, epo resulted in accelerated erythropoiesis. However, no alterations were observed in the circulating concentrations of neutrophils nor in the sizes of the NSP, NPP, or granulocytic progenitor pools. Fig. 3 . T h e effect of increasing concentrations of epo o n CFU-E generation, a n d S C M o n CFU-GM generation. EPO, erythropoietin; SCM, pokeweed mitogen-stimulated, spleen-cell conditioned medium. CFU-E colonies that developed in various concentrations of E P O a n d C F U -G M colonies that developed in various concentrations SCM are shown. Mean values are represented by solid circles a n d the brackets represent SEM. The discrepancy between the effects of epo on neutrophil production in vitro and in vivo cannot be explained by our studies. It is possible that, despite dosages of 2000 IU/kg, the concentrations of epo achieved in vivo in the marrow microenvironment are not comparable to those required to achieve downmodulation of neutrophil generation in vitro. Alternatively, it may be that the relationship between epo and granulocytopoiesis in culture fails to reflect the complex interactions between hematopoietic progenitors and growth factors in vivo (32, 33) .
Despite our lack of evidence of down-modulation of granulocytopoiesis by epo administration to weanling rats, we suggest that neutrophil production be monitored in clinical trials of epo administration to anemic neonates.
